Mylan Pushes For Mediation In EpiPen Antitrust Suit

Law360 (May 18, 2020, 10:53 PM EDT) -- Mylan has urged a Kansas federal judge to compel a pharmacy operator to mediate its proposed class action over the price of emergency allergy medication EpiPen, saying the company is bound by a contract that requires it to enter mediation before filing a suit. 

Mylan, which sells EpiPen, argued in a Friday motion that KPH Healthcare Services Inc. has no independent claims against it or Pfizer, which makes the medication. The motion contends that the retail and online pharmacy operator filed its February complaint as an assignee of McKesson Corp., which purchased EpiPen and other products from Mylan, and is bound...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!